Loading the company…
Loading the company…
Families: Cholecystectomy & appendectomy, Hysterectomy, hysteroscopy & ablation, Bariatric surgery, Antireflux & hiatal hernia surgery, Colorectal resection, Bronchoscopy & lung nodule.
All companies · Product and company coverage
In2Bones's surgeons now deal with CONMED. Integration brings new reps, contracts and bundles: for a competitor, a window while it settles; for CONMED, surgeons to keep.
CONMED press release · closing date to confirm
Payments and FDA records read by the company that owns the business today, so a deal never looks like surgeons switching; a surgeon’s payment history still shows the name each payment was made under.
In the last ten years FDA made 59 decisions for CONMED (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 5 procedure families, the most in 2018 (11). The latest was on 2026-05-30.
In 2025, CONMED reported engagement with 4,091 surgeons and other clinicians in the states MedaRep covers, worth $2.2M in consulting, speaking, meals and travel for its device products, the most in Texas ($321K to 331). Royalties are left out.
| CONMED Argo Knotless® Anchor |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to CONMED.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Texas ($321K, 331 engaged), Florida ($200K, 513 engaged), Connecticut ($181K, 75 engaged), New York ($177K, 247 engaged), California ($148K, 405 engaged).